Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Other Non-Current Assets (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Other Non-Current Assets data on record, last reported at $2.8 million in Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 106.01% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 106.01% increase, with the full-year FY2025 number at $2.8 million, up 106.01% from a year prior.
  • Other Non-Current Assets reached $2.8 million in Q4 2025 per NBP's latest filing, up from $1.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for NBP hit a ceiling of $4.2 billion in Q4 2021 and a floor of $464000.0 in Q2 2024.
  • A 5-year average of $321.8 million and a median of $1.3 million in 2025 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 1373416.16% in 2021, then plummeted 99.92% in 2022.
  • Tracing NBP's Other Non-Current Assets over 5 years: stood at $4.2 billion in 2021, then tumbled by 99.92% to $3.5 million in 2022, then crashed by 83.08% to $594715.8 in 2023, then surged by 129.52% to $1.4 million in 2024, then surged by 106.01% to $2.8 million in 2025.
  • Business Quant data shows Other Non-Current Assets for NBP at $2.8 million in Q4 2025, $1.1 million in Q3 2025, and $1.2 million in Q2 2025.